nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluocinolone Acetonide—PLA2G4A—amyotrophic lateral sclerosis	0.892	1	CbGaD
Fluocinolone Acetonide—Condition aggravated—Riluzole—amyotrophic lateral sclerosis	0.0119	0.144	CcSEcCtD
Fluocinolone Acetonide—Panophthalmitis—Riluzole—amyotrophic lateral sclerosis	0.0089	0.108	CcSEcCtD
Fluocinolone Acetonide—Fungal skin infection—Riluzole—amyotrophic lateral sclerosis	0.0052	0.0631	CcSEcCtD
Fluocinolone Acetonide—Endophthalmitis—Riluzole—amyotrophic lateral sclerosis	0.00456	0.0554	CcSEcCtD
Fluocinolone Acetonide—Blepharitis—Riluzole—amyotrophic lateral sclerosis	0.00353	0.0429	CcSEcCtD
Fluocinolone Acetonide—Mania—Riluzole—amyotrophic lateral sclerosis	0.00299	0.0363	CcSEcCtD
Fluocinolone Acetonide—Glaucoma—Riluzole—amyotrophic lateral sclerosis	0.00289	0.035	CcSEcCtD
Fluocinolone Acetonide—Abscess—Riluzole—amyotrophic lateral sclerosis	0.00275	0.0333	CcSEcCtD
Fluocinolone Acetonide—SERPINA6—hindbrain—amyotrophic lateral sclerosis	0.00229	0.165	CbGeAlD
Fluocinolone Acetonide—Cataract—Riluzole—amyotrophic lateral sclerosis	0.00228	0.0277	CcSEcCtD
Fluocinolone Acetonide—Neck pain—Riluzole—amyotrophic lateral sclerosis	0.0022	0.0267	CcSEcCtD
Fluocinolone Acetonide—Dermatitis contact—Riluzole—amyotrophic lateral sclerosis	0.00215	0.0261	CcSEcCtD
Fluocinolone Acetonide—Photophobia—Riluzole—amyotrophic lateral sclerosis	0.00204	0.0248	CcSEcCtD
Fluocinolone Acetonide—Ear pain—Riluzole—amyotrophic lateral sclerosis	0.00185	0.0224	CcSEcCtD
Fluocinolone Acetonide—Eczema—Riluzole—amyotrophic lateral sclerosis	0.00176	0.0213	CcSEcCtD
Fluocinolone Acetonide—Diplopia—Riluzole—amyotrophic lateral sclerosis	0.00158	0.0191	CcSEcCtD
Fluocinolone Acetonide—Influenza—Riluzole—amyotrophic lateral sclerosis	0.00136	0.0165	CcSEcCtD
Fluocinolone Acetonide—NR3C1—nerve—amyotrophic lateral sclerosis	0.00134	0.0967	CbGeAlD
Fluocinolone Acetonide—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00122	0.0147	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00122	0.0147	CcSEcCtD
Fluocinolone Acetonide—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.00114	0.0138	CcSEcCtD
Fluocinolone Acetonide—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.00109	0.0133	CcSEcCtD
Fluocinolone Acetonide—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00107	0.013	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.00102	0.0124	CcSEcCtD
Fluocinolone Acetonide—NR3C1—hindbrain—amyotrophic lateral sclerosis	0.001	0.0725	CbGeAlD
Fluocinolone Acetonide—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000983	0.0119	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.000964	0.0117	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.000956	0.0116	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00095	0.0115	CcSEcCtD
Fluocinolone Acetonide—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.00093	0.0113	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—medulla oblongata—amyotrophic lateral sclerosis	0.00092	0.0664	CbGeAlD
Fluocinolone Acetonide—Back pain—Riluzole—amyotrophic lateral sclerosis	0.000919	0.0111	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Acyl chain remodelling of PC—PLB1—amyotrophic lateral sclerosis	0.000903	0.0836	CbGpPWpGaD
Fluocinolone Acetonide—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.000853	0.0104	CcSEcCtD
Fluocinolone Acetonide—Cough—Riluzole—amyotrophic lateral sclerosis	0.000829	0.0101	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—spinal cord—amyotrophic lateral sclerosis	0.00082	0.0592	CbGeAlD
Fluocinolone Acetonide—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.000809	0.00981	CcSEcCtD
Fluocinolone Acetonide—Oedema—Riluzole—amyotrophic lateral sclerosis	0.000775	0.00941	CcSEcCtD
Fluocinolone Acetonide—Infection—Riluzole—amyotrophic lateral sclerosis	0.00077	0.00935	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00076	0.00922	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000706	0.00857	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—nervous system—amyotrophic lateral sclerosis	0.000691	0.0499	CbGeAlD
Fluocinolone Acetonide—SERPINA6—nervous system—amyotrophic lateral sclerosis	0.000688	0.0497	CbGeAlD
Fluocinolone Acetonide—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000669	0.00812	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—central nervous system—amyotrophic lateral sclerosis	0.000666	0.048	CbGeAlD
Fluocinolone Acetonide—Pain—Riluzole—amyotrophic lateral sclerosis	0.000663	0.00804	CcSEcCtD
Fluocinolone Acetonide—SERPINA6—central nervous system—amyotrophic lateral sclerosis	0.000663	0.0478	CbGeAlD
Fluocinolone Acetonide—SERPINA6—cerebellum—amyotrophic lateral sclerosis	0.000648	0.0467	CbGeAlD
Fluocinolone Acetonide—NR3C1—embryo—amyotrophic lateral sclerosis	0.000628	0.0453	CbGeAlD
Fluocinolone Acetonide—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—RAB5A—amyotrophic lateral sclerosis	0.000615	0.0569	CbGpPWpGaD
Fluocinolone Acetonide—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000613	0.00744	CcSEcCtD
Fluocinolone Acetonide—Fluticasone Propionate—PLA2G4A—amyotrophic lateral sclerosis	0.00059	0.651	CrCbGaD
Fluocinolone Acetonide—NR3C1—brainstem—amyotrophic lateral sclerosis	0.000576	0.0415	CbGeAlD
Fluocinolone Acetonide—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000571	0.00693	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000549	0.00666	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00053	0.00644	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—brain—amyotrophic lateral sclerosis	0.000528	0.0381	CbGeAlD
Fluocinolone Acetonide—SERPINA6—brain—amyotrophic lateral sclerosis	0.000526	0.038	CbGeAlD
Fluocinolone Acetonide—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000513	0.00622	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000493	0.00598	CcSEcCtD
Fluocinolone Acetonide—Rash—Riluzole—amyotrophic lateral sclerosis	0.000489	0.00593	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000488	0.00593	CcSEcCtD
Fluocinolone Acetonide—Headache—Riluzole—amyotrophic lateral sclerosis	0.000486	0.00589	CcSEcCtD
Fluocinolone Acetonide—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000461	0.00559	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Nuclear Receptors—RARA—amyotrophic lateral sclerosis	0.000438	0.0406	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—medulla oblongata—amyotrophic lateral sclerosis	0.000401	0.029	CbGeAlD
Fluocinolone Acetonide—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—ATF1—amyotrophic lateral sclerosis	0.000389	0.036	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—spinal cord—amyotrophic lateral sclerosis	0.000358	0.0258	CbGeAlD
Fluocinolone Acetonide—PLA2G4A—Phospholipid metabolism—SACM1L—amyotrophic lateral sclerosis	0.000357	0.0331	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Nuclear Receptor transcription pathway—RARA—amyotrophic lateral sclerosis	0.000346	0.0321	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—ATF1—amyotrophic lateral sclerosis	0.000337	0.0312	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Phospholipid metabolism—FIG4—amyotrophic lateral sclerosis	0.000336	0.0311	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Glycerophospholipid biosynthesis—PLB1—amyotrophic lateral sclerosis	0.00033	0.0305	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—nervous system—amyotrophic lateral sclerosis	0.000302	0.0218	CbGeAlD
Fluocinolone Acetonide—NR3C1—central nervous system—amyotrophic lateral sclerosis	0.00029	0.0209	CbGeAlD
Fluocinolone Acetonide—NR3C1—cerebellum—amyotrophic lateral sclerosis	0.000284	0.0205	CbGeAlD
Fluocinolone Acetonide—PLA2G4A—Glycerophospholipid biosynthesis—CHAT—amyotrophic lateral sclerosis	0.00025	0.0231	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—brain—amyotrophic lateral sclerosis	0.00023	0.0166	CbGeAlD
Fluocinolone Acetonide—PLA2G4A—Phospholipid metabolism—PLB1—amyotrophic lateral sclerosis	0.00023	0.0213	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—RAB5A—amyotrophic lateral sclerosis	0.000222	0.0206	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—CASP12—amyotrophic lateral sclerosis	0.000209	0.0193	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—CASP9—amyotrophic lateral sclerosis	0.000193	0.0179	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Phospholipid metabolism—CHAT—amyotrophic lateral sclerosis	0.000175	0.0161	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—ECE1—amyotrophic lateral sclerosis	0.000174	0.0161	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—SOD1—amyotrophic lateral sclerosis	0.000173	0.016	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—RARA—amyotrophic lateral sclerosis	0.00017	0.0158	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Prostaglandin Synthesis and Regulation—PTGS2—amyotrophic lateral sclerosis	0.000165	0.0152	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—RARA—amyotrophic lateral sclerosis	0.000164	0.0152	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—TUBA4A—amyotrophic lateral sclerosis	0.000151	0.014	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—ZNF470—amyotrophic lateral sclerosis	0.00015	0.0139	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—PTGS2—amyotrophic lateral sclerosis	0.000146	0.0135	CbGpPWpGaD
Fluocinolone Acetonide—Triamcinolone—PTGS2—amyotrophic lateral sclerosis	0.000138	0.152	CrCbGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—PFN1—amyotrophic lateral sclerosis	0.000136	0.0126	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000135	0.0125	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000124	0.0115	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	0.000117	0.0108	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000115	0.0106	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—ZNF746—amyotrophic lateral sclerosis	0.000114	0.0105	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	0.000114	0.0105	CbGpPWpGaD
Fluocinolone Acetonide—Betamethasone—PTGS2—amyotrophic lateral sclerosis	0.000113	0.124	CrCbGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—KIFAP3—amyotrophic lateral sclerosis	0.000113	0.0104	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—AQP4—amyotrophic lateral sclerosis	0.000112	0.0104	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—CHAT—amyotrophic lateral sclerosis	0.000112	0.0104	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—SLC1A3—amyotrophic lateral sclerosis	0.000112	0.0104	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	0.000109	0.0101	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000108	0.01	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	0.000107	0.00989	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—TP53—amyotrophic lateral sclerosis	8.67e-05	0.00802	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	8.26e-05	0.00764	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—CASP3—amyotrophic lateral sclerosis	8.14e-05	0.00753	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—TUBA4A—amyotrophic lateral sclerosis	7.81e-05	0.00722	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—MMP9—amyotrophic lateral sclerosis	7.69e-05	0.00712	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	7.41e-05	0.00686	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—RAB5A—amyotrophic lateral sclerosis	7.26e-05	0.00672	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—ZNF470—amyotrophic lateral sclerosis	7.24e-05	0.0067	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—PFN1—amyotrophic lateral sclerosis	7.03e-05	0.0065	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	6.96e-05	0.00644	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—SOD1—amyotrophic lateral sclerosis	6.59e-05	0.0061	CbGpPWpGaD
Fluocinolone Acetonide—Dexamethasone—PTGS2—amyotrophic lateral sclerosis	6.56e-05	0.0724	CrCbGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—SMN1—amyotrophic lateral sclerosis	6.15e-05	0.00569	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—VAPB—amyotrophic lateral sclerosis	6.03e-05	0.00558	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—TPK1—amyotrophic lateral sclerosis	6.03e-05	0.00558	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—RARA—amyotrophic lateral sclerosis	5.98e-05	0.00554	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	5.79e-05	0.00536	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	5.62e-05	0.0052	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—VAPA—amyotrophic lateral sclerosis	5.51e-05	0.0051	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—ZNF746—amyotrophic lateral sclerosis	5.48e-05	0.00507	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—MMP9—amyotrophic lateral sclerosis	5.19e-05	0.0048	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—SACM1L—amyotrophic lateral sclerosis	5.12e-05	0.00474	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—FIG4—amyotrophic lateral sclerosis	4.82e-05	0.00446	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	4.52e-05	0.00418	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—DAO—amyotrophic lateral sclerosis	4.36e-05	0.00403	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—IGF1—amyotrophic lateral sclerosis	4.35e-05	0.00402	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	4.02e-05	0.00372	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—HNRNPA1—amyotrophic lateral sclerosis	3.8e-05	0.00352	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	3.75e-05	0.00347	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	3.54e-05	0.00328	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—FUS—amyotrophic lateral sclerosis	3.53e-05	0.00327	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—TP53—amyotrophic lateral sclerosis	3.52e-05	0.00326	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	3.48e-05	0.00322	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—EXOSC9—amyotrophic lateral sclerosis	3.42e-05	0.00317	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—SOD1—amyotrophic lateral sclerosis	3.4e-05	0.00314	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PLB1—amyotrophic lateral sclerosis	3.3e-05	0.00306	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—TP53—amyotrophic lateral sclerosis	3.1e-05	0.00287	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—GSR—amyotrophic lateral sclerosis	3.05e-05	0.00282	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	2.95e-05	0.00273	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	2.89e-05	0.00268	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—RARA—amyotrophic lateral sclerosis	2.88e-05	0.00267	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	2.76e-05	0.00255	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	2.63e-05	0.00243	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	2.6e-05	0.0024	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—CHAT—amyotrophic lateral sclerosis	2.5e-05	0.00232	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—VCP—amyotrophic lateral sclerosis	2.46e-05	0.00228	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	2.46e-05	0.00227	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	2.38e-05	0.00221	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.28e-05	0.00211	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	2.23e-05	0.00206	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	2.12e-05	0.00196	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	2.09e-05	0.00194	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—IGF1—amyotrophic lateral sclerosis	2.07e-05	0.00192	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.56e-05	0.00145	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—C3—amyotrophic lateral sclerosis	1.55e-05	0.00143	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.44e-05	0.00133	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—VEGFA—amyotrophic lateral sclerosis	1.35e-05	0.00125	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.35e-05	0.00125	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.35e-05	0.00124	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.28e-05	0.00119	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.1e-05	0.00102	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—TP53—amyotrophic lateral sclerosis	1.02e-05	0.000946	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—APOE—amyotrophic lateral sclerosis	1.02e-05	0.000941	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—C3—amyotrophic lateral sclerosis	9.13e-06	0.000845	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	8.5e-06	0.000787	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	7.03e-06	0.00065	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PTGS2—amyotrophic lateral sclerosis	6.97e-06	0.000645	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	5.41e-06	0.0005	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	5.11e-06	0.000473	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.59e-06	0.000425	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.47e-06	0.000321	CbGpPWpGaD
